MBX Biosciences Appoints Steve Hoerter as Chairman and CEO, John Smither as CFO
The moves are aimed at supporting the company’s next phase of growth in precision peptide therapies.
/ 6 items
#MBX↓
MBX Biosciences’ Canvuparatide Shows Solid One-Year Data but Misses Market Expectations
MBX reports 57% response at 1 year for canvuparatide in hypoparathyroidism with stable safety, but shares fell on modest results.
MBX Biosciences Just Took a Big Step Toward Monthly Obesity Injections
MBX drug showed early weight loss up to 7% in 8 weeks, was well tolerated, and may become once-monthly treatment.
Goldman Sachs Initiates Sell Rating on MBX Biosciences
Goldman Sachs starts coverage of MBX Biosciences with a Sell rating and $18 price target, citing cautious outlook ahead of key trial data in 2026.
Truist Initiates MBX Biosciences Coverage with $50 Price Target
Truist analyst sets Buy rating on MBX Biosciences with $50 target, citing strong potential for lead drug canvuparatide (MBX 2109) with projected $3.2B peak sales by 2036.
MBX Biosciences Advances Hypoparathyroidism Treatment to Phase 3
Once-weekly canvuparatide for hypoparathyroidism met its Phase 2 goal. 63% of patients achieved stable calcium and cut daily supplements. It was well tolerated and is advancing to Phase 3.